IGM Biosciences Announces First Quarter 2020 Financial Results and Provides Corporate Update
May 07, 2020 16:03 ET
|
IGM Biosciences
- Initial data from Phase 1 trial of IGM-2323 in relapsed/refractory non-Hodgkin’s lymphoma expected in the second half of 2020 - - IND filing for IGM-8444 planned in 2020 - - Collaboration with...
Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on Novel Antibody Treatment for COVID-19
April 29, 2020 16:05 ET
|
IGM Biosciences
- Companies to utilize proprietary platforms to discover, develop, and manufacture potential therapeutic antibodies to combat ongoing COVID-19 pandemic - SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE,...
IGM Biosciences to Participate in Canaccord Genuity Horizons in Oncology Virtual Event
April 03, 2020 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., April 03, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 26, 2020 16:05 ET
|
IGM Biosciences
- Initial data from Phase 1 trial of IGM-2323 in relapsed/refractory non-Hodgkin’s lymphoma expected in the second half of 2020 - - IND filing for IGM-8444 planned in 2020 - - Company to host...
IGM Biosciences to Announce Fourth Quarter and Year-end 2019 Financial Results and Host Conference Call and Webcast on March 26, 2020
March 19, 2020 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., March 19, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences to Present at Two Upcoming Investor Conferences
March 04, 2020 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences to Present at Two Upcoming Investor Conferences
February 06, 2020 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a global leader in the research and development of engineered therapeutic IgM antibodies, today...
IGM Biosciences Appoints Eric Humke, M.D., Ph.D., as Vice President, Clinical Development, Apoptosis
January 07, 2020 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a global leader in the research and development of engineered therapeutic IgM antibodies, today...
IGM Biosciences to Present at Three Upcoming Investor Conferences
November 12, 2019 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for...
IGM Biosciences Announces Third Quarter 2019 Financial Results
November 07, 2019 17:04 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for...